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Previous observational studies using differing methodologies
have yielded inconsistent results regarding the association
between glycemic control and outcomes in diabetic patients
receiving maintenance hemodialysis (MHD). We examined mor-
tality predictability of A1C and random serum glucose over time
in a contemporary cohort of 54,757 diabetic MHD patients (age
63 6 13 years, 51% men, 30% African Americans, 19% Hispanics).
Adjusted all-cause death hazard ratio (HR) for baseline A1C
increments of 8.0–8.9, 9.0–9.9, and $10%, compared with 7.0–
7.9% (reference), was 1.06 (95% CI 1.01–1.12), 1.05 (0.99–1.12),
and 1.19 (1.12–1.28), respectively, and for time-averaged A1C was
1.11 (1.05–1.16), 1.36 (1.27–1.45), and 1.59 (1.46–1.72). A symmet-
ric increase in mortality also occurred with time-averaged A1C
levels in the low range (6.0–6.9%, HR 1.05 [95% CI 1.01–1.08]; 5.0–
5.9%, 1.08 [1.04–1.11], and #5%, 1.35 [1.29–1.42]) compared with
7.0–7.9% in fully adjusted models. Adjusted all-cause death HR for
time-averaged blood glucose 175–199, 200–249, 250–299, and
$300 mg/dL, compared with 150–175 mg/dL (reference), was
1.03 (95% CI 0.99–1.07), 1.14 (1.10–1.19), 1.30 (1.23–1.37), and
1.66 (1.56–1.76), respectively. Hence, poor glycemic control
(A1C $8% or serum glucose $200 mg/dL) appears to be associ-
ated with high all-cause and cardiovascular death in MHD
patients. Very low glycemic levels are also associated with high
mortality risk. Diabetes 61:708–715, 2012
D
iabetes is a potent cardiovascular risk factor
in the general population as well as in people
with end-stage renal disease (ESRD) undergoing
maintenance dialysis treatment (1–5). Clinical
trials have shown that tight glycemic control decreases
the risk of developing retinopathy, nephropathy, and neu-
ropathy in the general population (6,7). Furthermore, gly-
cemic control—as measured by A1C—is a predictor of
cardiovascular complications, including myocardial in-
farctions and hospitalizations for coronary artery disease
(1,8). Some guidelines, such as those of the National Kid-
ney Foundation Kidney Disease Outcomes Quality Initia-
tive (KDOQI), have recommended that diabetic dialysis
patients should follow the American Diabetes Association
guidelines; however, there is no consistent evidence to
support these recommendations for patients with ESRD (9–
12). This lack of evidence is highlighted by the KDOQI
recommendations, last updated in 2007, stating that “target
A1C for people with diabetes should be ,7%, irrespective of
presence or absence CKD [chronic kidney disease]” (13).
There are several issues unique to the dialysis popu-
lation that obligate a separate examination of glycemic
control on outcomes in this cohort. Insulin and glucose
homeostasis are affected by uremia, which may aggravate
insulin resistance (14). Moreover, it may be difﬁcult to
accurately assess glycemic control in this population be-
cause of changes in erythrocyte survival in renal failure
and the effects of erythropoiesis-stimulating agents on A1C
levels (14,15).
Recently, three large randomized trials have indicated
that intensive glucose lowering in patients with type 2 di-
abetes did not reduce the risks of cardiovascular disease,
the most common source of ESRD mortality (16–19). Ad-
ditionally, Williams and colleagues (20,21) reported a higher
risk of death only in diabetic hemodialysis patients with
A1C levels .11%. Shurraw et al. (22) found that higher
casual glucose and A1C levels were not associated with
mortality in maintenance hemodialysis (MHD) patients
with or without diabetes. In contrast, we reported that
after adjusting for potential confounders, higher A1C val-
ues were incrementally associated with higher death risks
in patients on MHD (23). These large observational studies
with differing methodologies and recruited patient pop-
ulations reached somewhat contrasting conclusions re-
garding the association of A1C with survival in diabetic
MHD patients. Hence, we undertook this study to further
examine the predictive value of glycemic control on all-
cause and cardiovascular mortality in a large, contempo-
rary cohort of MHD patients. This extended cohort study
also adds data on glucose levels, examines the effects of
anemia and race, and provides new subset analyses.
RESEARCH DESIGN AND METHODS
We extracted, reﬁned, and examined data from all individuals with ESRD who
underwent MHD treatment from July 2001 through June 2006 in any 1 of the 580
outpatient dialysis facilities of DaVita Inc., a large dialysis organization in the
U.S.(beforeitsacquisitionofunitsownedbyGambro).Thestudywasapproved
by relevant institutional review committees. Patients were included who had
been undergoing dialysis for at least 90 days, were being treated with MHD at
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ORIGINAL ARTICLEthe time of entry into the cohort, had a history of diabetes, and had at least one
A1C measurement in the ﬁrst quarter of entry into the cohort.
Clinical and demographic measures. The creation of the cohort has pre-
viously been described (24–26). To minimize measurement variability, all re-
peated measures for each patient during any given calendar quarter, i.e., over
a 13-week interval, were averaged and values were used in all models. Average
values were obtained from up to 20 calendar quarters (q1–q20) for each labo-
ratory and clinical measure for each patient over the 6-year cohort period.
The ﬁrst (baseline) studied quarter for each patient was the calendar quarter
in which the patient’s vintage reached .90 days. The presence or absence of
diabetes at baseline was obtained from DaVita Inc. data. Histories of tobacco
smoking and preexisting comorbid conditions were obtained by linking the
DaVita Inc. database to the Medical Evidence Form 2728 of the United States
Renal Data System, and the latter were categorized into 10 comorbid conditions:
ischemic heart disease, congestive heart failure, history of cardiac arrest, history
of myocardial infarction, pericarditis, cardiac dysrhythmia, cerebrovascular
events, peripheral vascular disease, chronic obstructive pulmonary disease, and
cancer (27).
Patients were followed for outcomes through 30 June 2007. The recorded
causes of death were obtained from the United States Renal Data System, and
cardiovascular death was deﬁned as death due to myocardial infarction,
cardiac arrest, heart failure, cerebrovascular accident, and other cardiac
causes.
Laboratory measures. Blood samples were drawn using uniform techniques
in all dialysis clinics and were transported to the DaVita Laboratory in Deland,
Florida, within 24 h. All laboratory values, including A1C, were measured by
automated and standardized methods. Most laboratory values were measured
monthly. A1C was usually measured quarterly or semiannually. We divided
patients into seven a priori categories based on A1C values: ,5a n d$10% and
1% increments in between, to examine the dose-response association between
A1C categories and death risk. Additional analyses were performed after
subdividing the population into two groups of A1C $7a n d,7 and A1C $6
and ,6%. We divided patients into eight a priori categories based upon ran-
domly measured serum glucose values (,100, 100 to ,125, 125 to ,150, 150
to ,175, 175 to ,200, 200 to ,250, 250 to ,300, and $300 mg/dL) to examine
the dose-response association between glucose categories and death risk.
Finally, additional analyses were performed after dividing the population into
two subgroups of glucose: $150 and ,150 mg/dL.
Epidemiologic and statistical methods. Survival analyses with Cox pro-
portional hazards regression with repeated quarterly measures were used to
examine whether glycemic control predicted survival for up to 6 years of
follow-up. The primary analysis examined the associations between baseline
A1C and glucose and all-cause mortality, with cardiovascular mortality serving
as a secondary outcome measure. We also performed exploratory analyses in
subgroups of patients based on age, sex, race, dialysis vintage, serum albumin
category (#3.8 or .3.8 g/dL), and anemia (serum hemoglobin #11 or .11 g/dL
and serum ferritin #500 or .500 ng/mL). We also performed exploratory
analyses according to race. To analyze the predictive value of time-averaged
A1C and glucose and assess the association between different laboratory and
clinical parameters and A1C levels, logistic regression analyses were per-
formed. For each analysis, including subgroup analyses, three models were
examined:
1) Unadjusted model that included mortality data, A1C/glucose categories,
and entry calendar quarter (q1–q20).
2) Case-mix–adjusted model that included all of the above plus age, sex, race/
ethnicity (African Americans and other self-categorized Blacks, Non-Hispanic
Caucasians, Asians, Hispanics, and others), categories of dialysis vintage
(,6 months, 6 months to 2 years, 2–5 years, and $5 years), primary in-
surance (Medicare, Medicaid, private, and others), marital status (married,
single, divorced, widowed, and other or unknown), dialysis dose as indi-
cated by Kt/V (single pool), and residual renal function during the entry
quarter, i.e., urinary urea clearance.
3) Case-mix plus malnutrition-inﬂammation-complex syndrome (MICS)–adjusted
model, which included all of the covariates in the case-mix model as well as
12 surrogates of nutritional status and inﬂammation, including BMI, total
nitrogen appearance (also known as normalized protein catabolic rate
[nPCR]), and 10 laboratory surrogates with known association with clinical
outcomes in hemodialysis patients (28) including serum levels of albumin,
total iron-binding capacity, ferritin, creatinine, phosphorus, calcium, bicar-
bonate, white blood cell count, lymphocyte percentage, and hemoglobin.
Missing covariate data were imputed by the multivariate regression impu-
tation method as appropriate. For all analysis, two-sided P values are reported
and results considered statistically signiﬁcant if P , 0.05. All statistical anal-
yses were carried out with SAS, version 9.1 (SAS Institute, Cary, NC).
RESULTS
Baseline data and correlations. Over the 5-year period
(July 2001–June 2006), 164,789 adult subjects received
dialysis treatment in units owned by DaVita Inc. (Supple-
mentary Fig. 1); of these, 141,762 patients were undergoing
MHD at the time of entry into the cohort. The study cohort
of 54,757 diabetic MHD patients (type 2 diabetes .96%)
was identiﬁed after excluding individuals without diabetes
(n = 61,519) and patients with diabetes without data on
A1C (n = 25,486). Of the 54,757 eligible patients who
formed the study cohort, 15,753 patients were prevalent in
the ﬁrst quarter (1 July 2001–30 September 2001) and
39,004 accumulated over the subsequent 19 quarters. The
median follow-up time was 886 days.
Table 1 shows baseline demographic, clinical, and lab-
oratory characteristics of the studied MHD patients accord-
ing to seven a priori categories based upon baseline A1C.
Higher A1C levels were associated with younger age,
fewer white and more Hispanic patients, and fewer Medi-
care patients.
We found moderate but signiﬁcant correlation between
serum glucose and A1C level (r = 0.562) (Supplementary
Fig. 2). In sensitivity analyses, we found relatively consis-
tent correlations across different glucose categories and in
different subgroups of patients (Supplementary Table 1).
Of the 54,657 MHD patients with A1C data, 50,383 also had
corresponding glucose data.
AlC and mortality. Figure 1A shows unadjusted and ad-
justed death hazard ratios (HRs) for groups based upon
baseline A1C. Case-mix– and MICS-adjusted all-cause death
HR for baseline A1C increments of 8.0–8.9, 9.0–9.9, and
$10%, compared with 7.0–7.9% (reference), was 1.06 (95%
CI 1.01–1.12), 1.05 (0.99–1.12), and 1.19 (1.12–1.28), re-
spectively. However, a time-averaged A1C $8% was as-
sociated with a higher risk of all-cause mortality (Fig. 1B).
In contrast with baseline analysis, an increased mortality
risk was found in patients with low time-averaged A1C
level. Case-mix– and MICS-adjusted all-cause death HR for
time-averaged A1C increments of 6.0–6.9, 5.0–5.9, and #5%,
compared with 7.0–7.9% (reference), was 1.05 (1.01–1.08),
1.08 (1.04–1.11), and 1.35 (1.29–1.42) (Fig. 1B).
Hemoglobin level ($11.0 or ,11.0 g/dL) was identiﬁed
as a nonsigniﬁcant modiﬁer of the time-averaged A1C–
mortality association (P value for interaction term, P =
0.67). In 43,806 or 80% of diabetic MHD patients, blood
hemoglobin was $11.0 g/dL. Supplementary Fig. 3A and B
shows the same analyses as shown in Fig. 1A for nonanemic
(A) and anemic (B) MHD patients. Among nonanemic
patients, time-averaged A1C levels of 8.0–8.9, 9.0–9.9,
and $10% were associated with 9, 33, and 57% higher all-
cause mortality, respectively (reference: A1C 7.0–7.9%; HR
1.09 [95% CI 1.03–1.15], 1.33 [1.23–1.43], and 1.57 [1.43–
1.72]). However, only time-averaged A1C $9% was asso-
ciated with a poor outcome in patients with hemoglobin
,11.0 g/dL.
Race was identiﬁed as a signiﬁcant modiﬁer of the time-
averaged A1C–mortality association (P value for interaction
terms: black, P = 0.02; white, P = 0.09; Hispanic, P = 0.03).
Supplementary Fig. 4A–C shows the same analyses as
shown in Fig. 1A for white (A), black (B), and Hispanic (C)
MHD patients. Among blacks and whites, time-averaged
A1C $8.0% was associated with higher all-cause mortality.
However, among high A1C values, only time-averaged
A1C $10% was associated with a poor outcome in Hispanic
patients. Subsequent subgroup analyses were performed to
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baseline A1C $7% among relevant demographic, clinical,
and laboratory categories of MHD patients (Fig. 2A). All
unadjusted analyses show that A1C .7% is protective
against all-cause mortality. However, this diminished or
reversed after adjustment for case-mix and MICS variables
in all subgroups. In the entire MHD population, the HR for
all-cause mortality in patients with baseline A1C $7% was
1.06 (95% CI 1.01–1.11) after adjustment for case-mix and
MICS variables. A1C $7% was associated with higher
mortality risk in white male patients, patients aged ,65
years, patients with albumin ,3.8 g/dL, and patients with
hemoglobin $11.0 g/dL.
We repeated the analyses using cardiovascular death as
the outcome. Figure 3A and B shows unadjusted and ad-
justed HRs according to the baseline and time-averaged
A1C values. Similarly to all-cause mortality, increased
cardiovascular mortality risk was associated with baseline
A1C $10% and time-averaged A1C $8%.
Glucose and mortality. Figure 1C shows unadjusted and
adjusted death HRs for groups based upon baseline glu-
cose. Case-mix– and MICS-adjusted all-cause death HR
for baseline glucose increments of 200–249, 250–299, and
$300 mg/dL, compared with 150–175 mg/dL (reference),
was 1.03 (95% CI 0.99–1.08), 1.04 (0.99–1.09), and 1.16
(1.10–1.22), respectively. However, a time-averaged glu-
cose $200 mg/dL was associated with a higher risk of all-
cause mortality (Fig. 1D).
Hemoglobin level ($11.0 or ,11.0 g/dL) was not iden-
tiﬁed as a signiﬁcant modiﬁer of the baseline glucose–
mortality association. Supplementary Fig. 5A and B shows
the same analyses as shown in Supplementary Fig. 3 for
nonanemic (A) and anemic (B) MHD patients. Among
anemic and nonanemic patients, a baseline glucose $200
mg/dL was associated with higher all-cause mortality (ref-
erence: glucose 150–175 mg/dL). Supplementary Fig. 6A–C
shows the same analyses as shown in Supplementary Fig. 4
for white (A), black (B), and Hispanic (C) MHD patients.
Subsequent subgroup analyses were performed to ex-
amine the HRs for all-cause mortality for patients with
baseline glucose $150 mg/dL among relevant demographic,
clinical, and laboratory categories of MHD patients including
race, sex, age, vintage, and selected laboratory measures
(Fig. 2B). In the entire MHD population, the HR for all-cause
mortality in patients with baseline glucose $150 mg/dL was
1.04 (95% CI 0.99–1.08) after adjustment for case-mix and
FIG. 1. HRs of all-cause mortality of the entire range of A1C in 54,757 MHD patients using standard Cox proportional hazards regression (A),
a time-averaged model (B), and HRs of all-cause mortality of serum glucose in 50,383 diabetic MHD patients using standard Cox proportional
hazards regression (C) and a time-averaged model (D). Case-mix model is adjusted for age, sex, race and ethnicity, categories of dialysis vintage,
primary insurance, marital status, dialysis dose as indicated by Kt/V (single pool), and residual renal function during the entry quarter. MICS-
adjusted model includes all of the case-mix covariates as well as BMI, nPCR, serum levels of albumin, total iron-binding capacity, ferritin, cre-
atinine, phosphorus, calcium, bicarbonate, blood white blood cell count, lymphocyte percentage, and hemoglobin.
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ciated with higher mortality risk in Hispanic patients and
patients with albumin ,3.8 g/dL.
We repeated the analyses using cardiovascular death as
the outcome. Figure 3C and D shows unadjusted and ad-
justed HRs according to the baseline and time-averaged
glucose values. Similarly to all-cause mortality, cardiovas-
cular mortality risk was associated with a baseline glucose
$300 mg/dL and a time-averaged glucose $200 mg/dL.
Correlates of low A1C. To examine the likelihood of
unusually low A1C in diabetic HD patients, we performed
a multivariate logistic regression analysis comparing the
odds of low (,6%) A1C to the nonlow A1C group ($6%)
(Table 2). In our case-mix–adjusted model, each gram per
deciliter increase in serum albumin (odds ratio 0.90 [0.86–
0.94]) and blood hemoglobin level (0.87 [0.86–0.88]), each
gram per kilogram per day increase of nPCR (0.55 [0.51–
0.59]), and each kilogram per meters squared increase in
BMI level (0.93 [0.92–0.94]) translated into a 10, 13, 45, and
7% lower risk of A1C level ,6%, respectively.
DISCUSSION
In this large-scale and contemporary cohort of 54,757 di-
abetic MHD patients, we report that a time-averaged A1C
$8% or time-averaged serum glucose $200 mg/dL appears
to be associated with higher all-cause and cardiovascular
mortality. This association was particularly robust in di-
abetic MHD patients with hemoglobin levels $11 g/dL.
Subgroup analyses showed that the baseline A1C thresh-
old for higher all-cause mortality was higher in Caucasians,
men, and patients with albumin level ,3.8 g/dL (A1C $7%).
We also report that the likelihood of having low baseline
A1C (,6%) was associated with lower values for BMI, al-
bumin, creatinine, and nPCR levels, indicating a link be-
tween A1C level and malnutrition and inﬂammation burden.
These ﬁndings may have important clinical implications,
especially since they imply that moderate hyperglycemia
may not be a risk factor for death for this population.
The literature on the relationship between glycemic con-
trol and survival in CKD population is somewhat limited.
However, a study using data from patients treated in units
owned by the Fresenius Group was unable to demonstrate
any association between A1C and 1-year survival in 24,875
hemodialysis patients (11). These ﬁndings contrast with
those of several other observational studies: Wu et al. (29)
studied 137 hemodialysis patients with type 2 diabetes and
reported that the cumulative survival was lower in the
group with poor glycemic control. Similarly, we have
previously shown that higher A1C is associated with in-
creased death risk in patients treated with hemodialysis in
time-dependent analyses (23). Recently, a study published
this year (30) that examined the time-dependent associa-
tion between A1C levels and mortality and cardiovascular
events in diabetic dialysis patients reported a signiﬁcantly
increased all-cause mortality among patients reporting
A1C levels ,6% (31,32). Additionally, Williams et al. (21)
reported a higher risk for death only in type 2 diabetic
hemodialysis patients with A1C levels .11% when using
baseline and time-dependent models. Moreover, we found in
a contemporary peritoneal dialysis population that only poor
glycemic control (A1C $8% and/or glucose $300 mg/dL)
appeared to be associated incrementally with lower sur-
vival in peritoneal dialysis patients (33). These studies pro-
vide additional evidence that very poor glycemic control is
associated with higher mortality in dialysis patients. How-
ever, peritoneal dialysis patients have a different glycemic
burden than MHD patients, including glucose load from the
peritoneal dialysate.
There are several possible mechanisms that might ex-
plain the relationship between glycemic control and sur-
vival of MHD patients. Poor glycemic control might result
directly in macrovascular complications, possibly second-
ary to the generation of advanced glycation end products
(AGEs), and, hence, shorten survival of these patients.
However, higher AGE levels in 312 hemodialysis patients
were found, paradoxically, to be associated with better
survival (34). The determination of whether the beneﬁto f
high serum AGEs in these types of observational studies is
an epiphenomenon or reﬂects a better nutritional status
requires further study. Furthermore, comorbid conditions
might make glycemic control unsatisfactory, and the higher
FIG. 2. HRs of all-cause mortality for the dichotomized A1C >7% in different subgroups of 54,757 MHD patients (A) and HRs of all-cause mortality
for the dichotomized glucose >150 mg/dL in different subgroups of 50,383 MHD patients (B). Fully adjusted model is controlled for age, sex, race
and ethnicity, categories of dialysis vintage, primary insurance, marital status, dialysis dose as indicated by Kt/V (single pool), residual renal
function during the entry quarter, BMI, nPCR, serum levels of albumin, total iron-binding capacity, ferritin, creatinine, phosphorus, calcium, bi-
carbonate, blood white blood cell count, lymphocyte percentage, and hemoglobin.
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rather than the poor glycemic control itself. An interven-
tional study of the impact of glycemic control is needed to
conﬁrm the reported ﬁndings.
In this observational study, we found that compared
with patients with A1C 7.0–7.9% (reference), patients with
time-averaged A1C increments of 6.0–6.9, 5.0–5.9, and #5%
had 5, 8, and 35% higher all-cause mortality risk, respectively.
A similar association was found in different observational
trials in dialysis populations (21,23,33). Moreover, in the
Action to Control Cardiovascular Risk in Diabetes
(ACCORD) trial, a prospective interventional study in
10,251 patients with diabetes and without renal failure
investigated whether A1C ,6%, to be attained by intensive
glucose control, reduces cardiovascular events and mor-
tality. Surprisingly, they found an increase in all-cause
mortality in the intensive therapy group compared with the
standard therapy group (16). There are at least two po-
tential mechanisms that might explain the relationship
between low A1C level and survival of MHD patients. It is
possible that intensive diabetes control increases the risk
for hypoglycemic episodes, which with increasing fre-
quency increases the risk of dying in the long-term follow-
up period. Another potential explanation is that low A1C
level is a surrogate marker of protein-energy wasting,
which is a well-know predictor of mortality in MHD
patients (35). This was supported by our observations. In
our logistic regression model, the markers of protein-
energy wasting such as albumin, creatinine, and BMI in-
dicated a correlation with having a low A1C level. After
adjusting the MICS covariables, we found that this asso-
ciation was abolished or sometimes inversed, indicating
that MICS is in the causal pathway.
The information on comorbidity in our study was limited
to that obtained from Medical Evidence Form 2728, a form
through which comorbid conditions are signiﬁcantly un-
derreported (36). Moreover, we did not have any data
available on the medications, if any, to treat diabetes or
their doses, and we did not study patient adherence with
therapy. Furthermore, the required dose of these medi-
cations can be confounded by the residual renal function
and its deterioration over time (37). Another potential
FIG. 3. HRs of cardiovascular mortality of the entire range of A1C in 54,757 MHD patients using standard Cox proportional hazards regression (A),
a time-averaged model (B), and HRs of cardiovascular mortality of serum glucose in 50,383 diabetic MHD patients using standard Cox proportional
hazards regression (C) and a time-averaged model (D). Case-mix model is adjusted for age, sex, race and ethnicity, categories of dialysis vintage,
primary insurance, marital status, dialysis dose as indicated by Kt/V (single pool), and residual renal function during the entry quarter. MICS-
adjusted model includes all of the case-mix covariates as well as BMI, nPCR, serum levels of albumin, total iron-binding capacity, ferritin, cre-
atinine, phosphorus, calcium, bicarbonate, blood white blood cell count, lymphocyte percentage, and hemoglobin.
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A1C and glucose as well as a lack of explicit laboratory
markers of inﬂammation such as C-reactive protein. How-
ever, we used data on serum albumin, ferritin, total iron-
binding capacity, blood white blood cell count, lymphocyte
percentage, and hemoglobin, which have signiﬁcant associ-
ations with inﬂammation in dialysis patients (28). Moreover,
it is known that A1C signiﬁcantly underestimates glycemic
control in hemodialysis patients (38). Finally, the use of time-
averaged measures in this analysis allowed us to reduce
variability observed over time and to examine overall trends
in the association between glycemic control and mortality;
however, these methods may mask signiﬁcant increases or
decreases in laboratory parameters important to survival.
In conclusion, poor glycemic control (A1C $8% or se-
rum glucose $200 mg/dL) appears to be associated with
decreased survival in the general population of diabetic
MHD patients. Our study suggests that moderate hyper-
glycemia increases the risk for all-cause or cardiovascular
mortality of diabetic MHD patients, especially in certain
subgroups (Caucasians, men, and those with serum albu-
min #3.8 g/dL). Moreover, the presence of protein-energy
wasting contributes to the higher risk of low (,6%) A1C
level. Admittedly, mortality is only one measure of the
deleterious impact of poor glycemic control. Other po-
tential beneﬁts of glycemic control, including slowing the
rate of progression of microvascular disease and rate of
loss of residual renal function, are possible and were not
TABLE 2
Multivariate logistic regression models showing clinical parameters and their odds ratios (95% CI) for low (,6%) A1C compared with
the nonlow A1C group ($6%) as reference
Unadjusted Case-mix adjusted Case-mix and MICS adjusted
Age (+1 year) 1.02 (1.02–1.03) 1.03 (1.02–1.03) 1.03 (1.03–1.03)
Female vs. male sex (reference) 1.04 (1.00–1.07) 0.98 (0.94–1.02) 1.00 (0.96–1.04)
Race
White Reference Reference Reference
Black 1.15 (1.11–1.19) 1.07 (1.02–1.11) 0.91 (0.87–0.96)
Hispanic 0.77 (0.74–0.81) 0.79 (0.75–0.83) 0.79 (0.75–0.84)
Asian 0.92 (0.83–1.01) 0.82 (0.74–0.91) 0.78 (0.70–0.87)
Dialysis vintage
0–6 months Reference Reference Reference
6–24 months 0.90 (0.87–0.93) 0.93 (0.88–0.98) 0.95 (0.90–1.01)
2–5 years 0.98 (0.95–1.02) 1.02 (0.96–1.08) 0.96 (0.91–1.02)
.5 years 1.13 (1.08–1.18) 1.16 (1.08–1.23) 0.93 (0.86–1.00)
Primary insurance
Medicare Reference Reference Reference
Medicaid 0.90 (0.83–0.97) 1.13 (1.04–1.23) 1.12 (1.03–1.22)
Private 0.96 (0.91–1.02) 1.02 (0.96–1.08) 1.02 (0.96–1.09)
Other 0.77 (0.73–0.81) 0.87 (0.82–0.92) 0.94 (0.89–0.99)
Marital status
Married Reference Reference Reference
Divorced 0.90 (0.84–0.96) 0.98 (0.91–1.05) 0.97 (0.90–1.04)
Single 0.92 (0.88–0.96) 1.09 (1.04–1.14) 1.08 (1.03–1.13)
Widowed 1.33 (1.27–1.40) 1.06 (1.00–1.12) 1.04 (0.99–1.10)
Presence of comorbidities
Hypertension 1.00 (0.95–1.04) 1.01 (0.97–1.06) 1.02 (0.97–1.06)
Inability to ambulate 1.40 (1.28–1.52) 1.26 (1.14–1.40) 1.25 (1.13–1.39)
Cerebrovascular disease 1.09 (1.03–1.16) 1.00 (0.94–1.07) 1.00 (0.94–1.06)
Other cardiac disease 1.21 (1.12–1.30) 1.12 (1.03–1.20) 1.13 (1.04–1.22)
Peripheral vascular disease 0.94 (0.90–0.99) 0.90 (0.86–0.95) 0.90 (0.85–0.95)
Cancer 1.55 (1.41–1.71) 1.30 (1.18–1.44) 1.24 (1.12–1.37)
Congestive heart failure 0.98 (0.94–1.10) 0.90 (0.87–0.94) 0.94 (0.90–0.98)
Atherosclerotic heart disease 0.98 (0.94–1.02) 0.88 (0.84–0.92) 0.89 (0.85–0.93)
Inability to transfer 1.68 (1.44–1.96) 1.27 (1.06–1.52) 1.25 (1.04–1.50)
Tobacco use 1.03 (0.94–1.12) 1.15 (1.05–1.26) 1.12 (1.02–1.23)
Pulmonary disease 1.20 (1.12–1.30) 1.09 (1.01–1.18) 1.13 (1.04–1.22)
Laboratory parameters
Delivered single-pool Kt/V (+1 increase) 0.98 (0.93–1.02) 0.90 (0.86–0.95) 1.12 (1.05–1.19)
Albumin (+1 g/dL increase) 0.90 (0.87–0.94) 0.90 (0.86–0.94) 1.09 (1.03–1.15)
Creatinine (+1 mg/dL increase) 1.02 (1.01–1.02) 1.05 (1.04–1.06) 1.08 (1.07–1.09)
Total iron-binding capacity (+100 mg/dL increase) 0.68 (0.67–0.69) 0.73 (0.71–0.74) 0.78 (0.76–0.78)
Bicarbonate (+1 mg/dL increase) 1.02 (1.01–1.03) 1.00 (0.99–1.01) 0.99 (0.98–1.00)
Phosphorus (+1 mg/dL increase) 0.95 (0.94–0.96) 1.00 (0.99–1.01) 1.01 (0.99–1.02)
Calcium (+1 mg/dL increase) 1.08 (1.05–1.10) 1.04 (1.01–1.06) 1.09 (1.06–1.12)
Protein catabolic rate (+1 g/kg/day increase) 0.54 (0.51–0.58) 0.55 (0.51–0.59) 0.45 (0.41–0.49)
Blood hemoglobin (+1 g/dL increase) 0.87 (0.86–0.88) 0.87 (0.86–0.88) 0.87 (0.86–0.88)
Lymphocyte (+1% of total WBCs) 1.00 (0.99–1.00) 1.00 (1.00–1.01) 1.00 (1.00–1.00)
BMI (+5 kg/m
2 increase) 0.92 (0.91–0.92) 0.93 (0.92–0.94) 0.93 (0.92–0.94)
WBCs, white blood cells.
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the target A1C levels in different subgroups of diabetic
MHD patients.
ACKNOWLEDGMENTS
This study was partly supported by a research grant from
the National Institutes of Health (DK077341) to K.K.-Z. K.K.-Z.
also receives funding from the National Institute of
Diabetes and Digestive and Kidney Diseases of the National
Institutes of Health (R01 DK078106) and a philanthropic
grant from Mr. Harold Simmons. M.Z.M. received grants
from the National Developmental Agency (KTIA-OTKA-EU
7KP-HUMAN-MB08-A-81231) from the Research and Tech-
nological Innovation Fund and was also supported by the
Hungarian Kidney Foundation.
This study was also supported by a research grant from
DaVita Inc. (to K.K.-Z.). No other potential conﬂicts of
interest relevant to this article were reported.
J.R., M.Z.M., C.P.K., and M.W. contributed to analysis
and interpretation of data and to writing the manuscript.
A.S. contributed to writing the manuscript. A.R.N. con-
tributed to analysis and interpretation of data. K.K.-Z.
designed, organized, and coordinated the study; managed
data entry; contributed to data analysis and interpretation
of data; and wrote the manuscript. K.K.-Z. is the guarantor
of this work and, as such, had full access to all the data in
the study and takes responsibility for the integrity of the
data and the accuracy of the data analysis.
Parts of this study were presented in abstract form at the
44th Annual Meeting of the American Society of Nephrol-
ogy, Philadelphia, Pennsylvania, 8–13 November 2011.
The authors thank DaVita Clinical Research for provid-
ing the clinical data, analysis, and review for this research
project.
REFERENCES
1. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multi-
factorial intervention and cardiovascular disease in patients with type 2
diabetes. N Engl J Med 2003;348:383–393
2. United States Renal Data System. Excerpts from the USRDS 2005 Annual
Data Report: Atlas of End-Stage Renal Disease in the United States, Na-
tional Institutes of Health, National Institute of Diabetes and Digestive and
Kidney Diseases. Am J Kid Dis 2006;47(Suppl. 1):1–286
3. Friedman EA. Renal syndromes in diabetes. Endocrinol Metab Clin North
Am 1996;25:293–324
4. Abbott KC, Bakris GL. Treatment of the diabetic patient: focus on cardio-
vascular and renal risk reduction. Prog Brain Res 2002;139:289–298
5. Kimmel PL, Varela MP, Peterson RA, et al. Interdialytic weight gain and
survival in hemodialysis patients: effects of duration of ESRD and diabetes
mellitus. Kidney Int 2000;57:1141–1151
6. Warram JH, Manson JE, Krolewski AS. Glycosylated hemoglobin and the
risk of retinopathy in insulin-dependent diabetes mellitus. N Engl J Med
1995;332:1305–1306
7. The Diabetes Control and Complications Trial Research Group. The effect
of intensive treatment of diabetes on the development and progression of
long-term complications in insulin-dependent diabetes mellitus. N Engl J
Med 1993;329:977–986
8. Chaturvedi N, Fuller JH; EURODIAB IDDM Complications Study Group.
Glycosylated hemoglobin and the risk of microalbuminuria in insulin-
dependent diabetes mellitus. N Engl J Med 1995;333:940–941
9. American Diabetes Association. Standards of medical care in diabetes—
2010. Diabetes Care 2010;33(Suppl. 1):S11–S61
10. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis
patients. Am J Kidney Dis 2005;45(Suppl. 3):S46–S48
11. Williams ME, Lacson E Jr, Teng M, Ofsthun N, Lazarus JM. Hemodialyzed
type I and type II diabetic patients in the US: characteristics, glycemic
control, and survival. Kidney Int 2006;70:1503–1509
12. Feldt-Rasmussen B. Is there a need to optimize glycemic control in he-
modialyzed diabetic patients? Kidney Int 2006;70:1392–1394
13. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations
for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007;49:S12–S154
14. Rubenstein AH, Mako ME, Horwitz DL. Insulin and the kidney. Nephron
1975;15:306–326
15. Ly J, Marticorena R, Donnelly S. Red blood cell survival in chronic renal
failure. Am J Kidney Dis 2004;44:715–719
16. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardio-
vascular Risk in Diabetes Study Group. Effects of intensive glucose low-
ering in type 2 diabetes. N Engl J Med 2008;358:2545–2559
17. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group.
Intensive blood glucose control and vascular outcomes in patients with
type 2 diabetes. N Engl J Med 2008;358:2560–2572
18. Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose
control and vascular complications in veterans with type 2 diabetes.
N Engl J Med 2009;360:129–139
19. Skyler JS, Bergenstal R, Bonow RO, et al.; American Diabetes Association;
American College of Cardiology Foundation; American Heart Association.
Intensive glycemic control and the prevention of cardiovascular events:
implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a posi-
tion statement of the American Diabetes Association and a Scientiﬁc
Statement of the American College of Cardiology Foundation and the
American Heart Association. J Am Coll Cardiol 2009;53:298–304
20. Ix JH. Hemoglobin A1C in hemodialysis patients: should one size ﬁt all?
Clin J Am Soc Nephrol 2010;5:1539–1541
21. Williams ME, Lacson E Jr, Wang W, Lazarus JM, Hakim R. Glycemic
control and extended hemodialysis survival in patients with diabetes
mellitus: comparative results of traditional and time-dependent Cox model
analyses. Clin J Am Soc Nephrol 2010;5:1595–1601
22. Shurraw S, Majumdar SR, Thadhani R, Wiebe N, Tonelli M; Alberta Kidney
Disease Network. Glycemic control and the risk of death in 1,484 patients
receiving maintenance hemodialysis. Am J Kidney Dis 2010;55:875–884
23. Kalantar-Zadeh K, Kopple JD, Regidor DL, et al. A1C and survival in
maintenance hemodialysis patients. Diabetes Care 2007;30:1049–1055
24. Molnar MZ, Streja E, Kovesdy CP, et al. High platelet count as a link be-
tween renal cachexia and cardiovascular mortality in end-stage renal
disease patients. Am J Clin Nutr 2011;94:945–954
25. Ricks J, Molnar MZ, Kovesdy CP, et al. Racial and ethnic differences in the
association of body mass index and survival in maintenance hemodialysis
patients. Am J Kidney Dis 2011;58:574–582
26. Streja E, Kovesdy CP, Molnar MZ, et al. Role of nutritional status and in-
ﬂammation in higher survival of African American and Hispanic hemodi-
alysis patients. Am J Kidney Dis 2011;57:883–893
27. Rattanasompattikul M, Feroze U, Molnar MZ, et al. Charlson comorbidity
score is a strong predictor of mortality in hemodialysis patients. Int Urol
Nephrol. 30 November 2011 [Epub ahead of print]
28. Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD,
Kalantar-Zadeh K. Association between serum lipids and survival in he-
modialysis patients and impact of race. J Am Soc Nephrol 2007;18:293–303
29. Wu MS, Yu CC, Yang CW, et al. Poor pre-dialysis glycaemic control is
a predictor of mortality in type II diabetic patients on maintenance hae-
modialysis. Nephrol Dial Transplant 1997;12:2105–2110
30. Sturm G, Lamina C, Zitt E, et al. Association of HbA1C values with mor-
tality and cardiovascular events in diabetic dialysis patients. The INVOR
study and review of the literature. PLoS ONE 2011;6:e20093
31. Kovesdy CP, Park JC, Kalantar-Zadeh K. Glycemic control and burnt-out
diabetes in ESRD. Semin Dial 2010;23:148–156
32. Kalantar-Zadeh K, Derose SF, Nicholas S, Benner D, Sharma K, Kovesdy CP.
Burnt-out diabetes: impact of chronic kidney disease progression on the
natural course of diabetes mellitus. J Ren Nutr 2009;19:33–37
33. Duong U, Mehrotra R, Molnar MZ, et al. Glycemic control and survival in
peritoneal dialysis patients with diabetes mellitus. Clin J Am Soc Nephrol
2011;6:1041–1048
34. Schwedler SB, Metzger T, Schinzel R, Wanner C. Advanced glycation end
products and mortality in hemodialysis patients. Kidney Int 2002;62:301–310
35. Rambod M, Bross R, Zitterkoph J, et al. Association of Malnutrition-
Inﬂammation Score with quality of life and mortality in hemodialysis pa-
tients: a 5-year prospective cohort study. Am J Kidney Dis 2009;53:298–309
36. Longenecker JC, Coresh J, Klag MJ, et al. Validation of comorbid conditions
on the end-stage renal disease medical evidence report: the CHOICE study.
Choices for Healthy Outcomes in Caring for ESRD. J Am Soc Nephrol 2000;
11:520–529
37. McMurray SD, Johnson G, Davis S, McDougall K. Diabetes education and
care management signiﬁcantly improve patient outcomes in the dialysis unit.
Am J Kidney Dis 2002;40:566–575
38. Freedman BI, Shenoy RN, Planer JA, et al. Comparison of glycated albu-
min and hemoglobin A1C concentrations in diabetic subjects on peritoneal
and hemodialysis. Perit Dial Int 2010;30:72–79
J. RICKS AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 61, MARCH 2012 715